文献速递静脉血栓栓塞慢性静脉疾病

深静脉反流治疗器械、设计与试验的系统综述

Systematic Review of Devices, Designs, and Trials for the Treatment of Deep Venous Reflux
RSS 订阅 · PubMed · J Vasc Surg Venous Lymphat Disord · 2026-10-19

该系统综述纳入15项研究(8项人体、7项动物),评估用于深静脉反流的假体或生物假体装置。人体研究技术成功率87.7%-100%,通畅率67%-100%,围术期并发症0%-44%。装置通畅与反流减少及临床改善间常不一致,少数患者达到预设反流减少终点。

要点

  • 人体研究技术成功率87.7%-100%,通畅率67%-100%,围术期并发症0%-44%。
  • 瓣膜闭塞在动物植入中高达28%,在部分人体队列中为18%-22%。
  • 解剖通畅、超声反流减少与临床改善之间常不一致,需综合评估。

核心结论

  • 深静脉反流装置在人体研究中显示较高技术成功率和通畅率,但瓣膜功能评估异质性强,解剖、血流动力学与患者中心结局常不一致。

研究设计与样本

  • PROSPERO注册的系统综述(CRD420251101761),检索6个数据库至2026年2月,纳入15项研究(8项人体、7项动物)。
  • 纳入评估假体或生物假体装置的体内动物和人体研究,排除自体瓣膜修复或自体移植研究。

主要发现

  • 人体研究技术成功率87.7%-100%,通畅率67%-100%,围术期并发症0%-44%,主要为出血、伤口感染和瓣膜血栓。
  • 瓣膜闭塞在动物植入中高达28%,在部分人体队列中为18%-22%;动物研究发生2例围术期死亡,人体研究未报告。
  • 人体研究中瓣膜 competency 评估方法差异大,报告的功能良好率0%-92%。
  • 当代多中心试验数据中,尽管装置通畅率高且临床改善明显,不足一半患者达到预设反流减少终点。
  • 1年时75%-97%患者疼痛改善,rVCSS降低37%-81%,高达84.6%达到临床有意义的≥3分改善。

临床怎么用

  • 现有证据支持深静脉反流装置可改善部分患者临床症状,但需注意解剖通畅与临床获益可能不一致。
  • 临床应用时应规范瓣膜功能评估方法,并综合解剖、血流动力学和患者报告结局判断疗效。

局限性

  • 瓣膜功能评估的影像模态和定义异质性大,导致功能良好率报告范围宽泛。
  • 解剖通畅、反流减少与临床改善间常不一致,可能影响终点解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

J Vasc Surg Venous Lymphat Disord . 2026 Oct 19:102643. doi: 10.1016/j.jvsv.2026.102643. Online ahead of print. ABSTRACT OBJECTIVE: Chronic venous insufficiency (CVI) is driven primarily by venous reflux and affects nearly one-third of adults. While superficial reflux is effectively treated with ablation, therapeutic options for deep venous reflux (DVR) remain limited. Despite decades of innovation, no prosthetic or bioprosthetic venous valve has achieved U.S. regulatory approval. We systematically reviewed device strategies, clinical and hemodynamic outcomes, complications, and barriers to translation for devices designed to treat DVR. METHODS: We conducted a PROSPERO-registered systematic review (CRD420251101761) of six databases from inception through February 2026, including in vivo animal and human studies evaluating prosthetic or bioprosthetic devices for DVR. Studies of native valve repair or autotransplantation were excluded. The primary outcome for human studies was clinical improvement, and secondary outcomes included patency, procedural complications, valvular function, and thrombosis. RESULTS: Of 516 records identified, 15 met inclusion criteria: 8 human and 7 animal studies. Two principal strategies were identified: intraluminal valve restoration (VR) and external compression (EC), with approximately 40% of devices delivered percutaneously or endovenously. In human studies, technical success ranged from 87.7%-100%, patency from 67%-100%, and perioperative complication rates from 0%-44%, consisting primarily of bleeding, wound infection, and valve thrombosis. Valve occlusion occurred in up to 28% of animal implants and 18%-22% of select human cohorts. Two perioperative deaths occurred in animal studies; none were reported in human studies. Among human studies, valve competency assessment methods varied substantially. Reported competency ranged from 0%-92%, reflecting heterogeneity in imaging modalities and definitions. Discordance between anatomic patency, duplex-derived reflux reduction, and clinical improvement was frequently observed. In contemporary multicenter trial data, fewer than half of patients met predefined reflux-reduction endpoints despite high device patency and substantial clinical improvement, highlighting discordance between anatomic, hemodynamic, and patient-centered outcomes. By one year, pain had improved in 75%-97% of patients; rVCSS decreased by 37%-81%, with clinically meaningful (≥3-point) improvement in up to 84.6%; an

来源:PubMed · J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. PubMed · J Vasc Surg Venous Lymphat Disord:Systematic Review of Devices, Designs, and Trials for the Treatment of Deep Venous Reflux

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。